A multi-metabolite analysis of serum by 1H NMR spectroscopy: Early systemic signs of Alzheimer's disease

Biochemical and Biophysical Research Communications

Volumn 375, Issue 3, 2008, Pages 356-361

  Tukiainen, Taru ^a   Tynkkynen, Tuulia ^b   Mäkinen, Ville Petteri ^a,c,d   Jylänki, Pasi ^a   Kangas, Antti ^a   Hokkanen, Johanna ^a   Vehtari, Aki ^a   Gröhn, Olli ^b   Hallikainen, Merja ^b   Soininen, Hilkka ^b   Kivipelto, Miia ^b   Groop, Per Henrik ^c,d   Kaski, Kimmo ^a   Laatikainen, Reino ^b   Soininen, Pasi ^b   Pirttilä, Tuula ^b   Ala Korpela, Mika ^a,c,d  

^a AALTO UNIVERSITY   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c FOLKHÄLSAN INSTITUTE OF GENETICS   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Alzheimer's disease; Lipid extracts; Lipoproteins; Metabolomics; Metabonomics; Mild cognitive impairment; NMR spectroscopy; Self organising map; Serum

Indexed keywords

DRUG METABOLITE; GLYCOPROTEIN; LIPID; LIPOPROTEIN; LOW MOLECULAR WEIGHT METABOLITE; OMEGA 3 FATTY ACID; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; COGNITIVE DEFECT; DISEASE ASSOCIATION; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; METABOLITE; NEUROPSYCHOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHENOTYPE; PRIORITY JOURNAL;

ALZHEIMER DISEASE; EARLY DIAGNOSIS; GLYCOPROTEINS; HUMANS; LIPOPROTEINS; MEMORY DISORDERS; METABOLIC SYNDROME X; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; SERUM;

EID: 50849141305     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.08.007     Document Type: Article

References (22)

1. 1H NMR metabonomics as a prognostic and diagnostic tool. Expert Rev. Mol. Diagn. 7 (2007) 761-773
2. 1H NMR metabonomics of serum as a methodology for disease risk assessment and diagnostics. Clin. Chem. Lab. Med. 46 (2008) 27-42
3. 1H NMR metabonomics approach to the disease continuum of diabetic complications and premature death. Mol. Syst. Biol. 4 (2008) 167
4. Holmes E., Loo R.L., Stamler J., Bictash M., Yap I.K., Chan Q., Ebbels T., De Iorio M., Brown I.J., Veselkov K.A., Daviglus M.L., Kesteloot H., Ueshima H., Zhao L., Nicholson J.K., and Elliott P. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 453 (2008) 396-400
5. Griffin J.L., and Vidal-Puig A. Current challenges in metabolomics for diabetes research: a vital functional genomic tool or just a ploy for gaining funding?. Physiol. Genomics 34 (2008) 1-5
6. Herukka S.K., Helisalmi S., Hallikainen M., Tervo S., Soininen H., and Pirttilä T. CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI. Neurobiol. Aging 28 (2007) 507-514
7. Shobab L.A., Hsiung G.Y., and Feldman H.H. Cholesterol in Alzheimer's disease. Lancet Neurol. 4 (2005) 841-852
8. Kivipelto M., and Solomon A. Cholesterol as a risk factor for Alzheimer's disease-epidemiological evidence. Acta Neurol. Scand. Suppl. 185 (2006) 50-57
9. Hänninen T., Hallikainen M., Tuomainen S., Vanhanen M., and Soininen H. Prevalence of mild cognitive impairment: a population-based study in elderly subjects. Acta Neurol. Scand. 106 (2002) 148-154
10. Folch J.S., Lees M., and Stanley H.S. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226 (1957) 497-509
11. Adosraku R.K., Choi G.T., Constantinou-Kokotos V., Anderson M.M., and Gibbons W.A. NMR lipid profiles of cells, tissues, and body fluids: proton NMR analysis of human erythrocyte lipids. J. Lipid Res. 35 (1994) 1925-1931
12. Mierisova S., and Ala-Korpela M. MR spectroscopy quantitation: a review of frequency domain methods. NMR Biomed. 14 (2001) 247-259
13. 1H NMR spectroscopy: constrained total-line-shape fitting. Anal. Chim. Acta 542 (2005) 178-185
14. 1H NMR metabonomic data. BMC Bioinform. 8S2 (2007) S8
15. Martins I.J., Hone E., Foster J.K., Sünram-Lea S.I., Gnjec A., Fuller S.J., Nolan D., Gandy S.E., and Martins R.N. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol. Psychiatry 11 (2006) 721-736
16. M.M. Mielke, V.V. Bandaru, N.J. Haughey, P.V. Rabins, C.G. Lyketsos, M.C. Carlson, Serum sphingomyelins and ceramides are early predictors of memory impairment, Neurobiol. Aging, in press.
17. Ravaglia G., Forti P., Maioli F., Bianchi G., Martelli M., Talerico T., Servadei L., Zoli M., and Mariani E. Plasma amino acid concentrations in patients with amnestic mild cognitive impairment or Alzheimer disease. Am. J. Clin. Nutr. 80 (2004) 483-488
18. Davis T.M.E., Jackson D., Davis W.A., Bruce D.G., and Chubb P. The relationship between metformin therapy and the fasting plasma lactate in type 2 diabetes: the fremantle diabetes study. Br. J. Clin. Pharmacol. 52 (2001) 137-144
19. Amenta F., and Tayebati S.K. Pathways of acetylcholine synthesis, transport and release as targets for treatment of adult-onset cognitive dysfunction. Curr. Med. Chem. 15 (2008) 488-498
20. Dik M.G., Jonker C., Hack C.E., Smit J.H., Comijs H.C., and Eikelenboom P. Serum inflammatory proteins and cognitive decline in older persons. Neurology 64 (2005) 1371-1377
21. Yaffe K., Kanaya A., Lindquist K., Simonsick E.M., Harris T., Shorr R.I., Tylavsky F.A., and Newman A.B. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 292 (2004) 2237-2242
22. Torri G.M., Torri J., Gulian J.M., Vion-Dury J., Viout P., and Cozzone P.J. Magnetic resonance spectroscopy of serum and acute-phase proteins revisited: a multiparametric statistical analysis of metabolite variations in inflammatory, infectious and miscellaneous diseases. Clin. Chim. Acta 279 (1999) 77-96